310 related articles for article (PubMed ID: 23377519)
1. Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone.
Makino ET; Herndon JH; Sigler ML; Gotz V; Garruto J; Mehta RC
J Drugs Dermatol; 2012 Dec; 11(12):1478-82. PubMed ID: 23377519
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone.
Makino ET; Mehta RC; Garruto J; Gotz V; Sigler ML; Herndon JH
J Drugs Dermatol; 2013 Mar; 12(3):s21-6. PubMed ID: 23545929
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of a novel multimodality hydroquinone-free skin brightener over six months.
Bruce S
J Drugs Dermatol; 2013 Mar; 12(3):S27-31. PubMed ID: 23545930
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of hydroquinone-free and hydroquinone-based hyperpigmentation regimens in treating facial hyperpigmentation and photoaging.
Fabi SG; Goldman MP
J Drugs Dermatol; 2013 Mar; 12(3):S32-7. PubMed ID: 23545931
[TBL] [Abstract][Full Text] [Related]
5. A Randomized, Investigator-Blinded Comparison of Two Topical Regimens in Fitzpatrick Skin Types III-VI With Moderate to Severe Facial Hyperpigmentation.
Vanaman Wilson MJ; Jones IT; Bolton J; Larsen L; Wu DC; Goldman MP
J Drugs Dermatol; 2017 Nov; 16(11):1127-1132. PubMed ID: 29141061
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a hydroquinone-free skin brightening product using in vitro inhibition of melanogenesis and clinical reduction of ultraviolet-induced hyperpigmentation.
Makino ET; Mehta RC; Banga A; Jain P; Sigler ML; Sonti S
J Drugs Dermatol; 2013 Mar; 12(3):s16-20. PubMed ID: 23545928
[TBL] [Abstract][Full Text] [Related]
7. Randomized, Double-Blinded, Split-Face Study Comparing the Efficacy and Tolerability of Two Topical Products for Melasma.
Kaufman BP; Alexis AF
J Drugs Dermatol; 2020 Sep; 19(9):822-827. PubMed ID: 33026755
[TBL] [Abstract][Full Text] [Related]
8. Tolerance and efficacy of a product containing ellagic and salicylic acids in reducing hyperpigmentation and dark spots in comparison with 4% hydroquinone.
Dahl A; Yatskayer M; Raab S; Oresajo C
J Drugs Dermatol; 2013 Jan; 12(1):52-8. PubMed ID: 23377328
[TBL] [Abstract][Full Text] [Related]
9. Comparison of a skin-lightening cream targeting melanogenesis on multiple levels to triple combination cream for melasma.
Monheit GD; Dreher F
J Drugs Dermatol; 2013 Mar; 12(3):270-4. PubMed ID: 23545908
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of two commercial hyperpigmentation kits in the treatment of facial hyperpigmentation and photo-aging.
Fabi S; Massaki N; Goldman MP
J Drugs Dermatol; 2012 Aug; 11(8):964-8. PubMed ID: 22859242
[TBL] [Abstract][Full Text] [Related]
11. Brightening and Improvement of Facial Skin Quality in Healthy Female Subjects With Moderate Hyperpigmentation or Dark Spots and Moderate Facial Aging.
Serra M; Bohnert K; Narda M; Granger C; Sadick N
J Drugs Dermatol; 2018 Dec; 17(12):1310-1315. PubMed ID: 30586263
[TBL] [Abstract][Full Text] [Related]
12. Novel skin brightener used as monotherapy for moderate melasma in skin of color.
Grimes PE
J Drugs Dermatol; 2014 Mar; 13(3):364-6. PubMed ID: 24595584
[TBL] [Abstract][Full Text] [Related]
13. Combination of In-Office Chemical Peels With a Topical Comprehensive Pigmentation Control Product in Skin of Color Subjects With Facial Hyperpigmentation.
Downie J; Schneider K; Goberdhan L; Makino ET; Mehta RC
J Drugs Dermatol; 2017 Apr; 16(4):301-306. PubMed ID: 28403262
[TBL] [Abstract][Full Text] [Related]
14. A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation.
Grimes PE
Cutis; 2004 Dec; 74(6):362-8. PubMed ID: 15663072
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the Safety and Efficacy of a Topical Formulation Containing Epidermal Growth Factor, Tranexamic Acid, Vitamin C, Arbutin, Niacinamide and Other Ingredients as Hydroquinone 4% Alternatives to Improve Hyperpigmentation: A Prospective, Randomized, Controlled Split Face Study.
Kalasho BD; Minokadeh A; Zhang-Nunes S; Zoumalan RA; Shemirani NL; Waldman AR; Pletzer V; Zoumalan CI
J Cosmet Sci; 2020; 71(5):263-290. PubMed ID: 33022197
[TBL] [Abstract][Full Text] [Related]
16. Assessment of a superficial chemical peel combined with a multimodal, hydroquinone-free skin brightener using in vivo reflectance confocal microscopy.
Goberdhan LT; Mehta RC; Aguilar C; Makino ET; Colvan L
J Drugs Dermatol; 2013 Mar; 12(3):S38-41. PubMed ID: 23545932
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a kojic acid, emblica extract, and glycolic acid formulation compared with hydroquinone 4% for skin lightening.
Draelos ZD; Yatskayer M; Bhushan P; Pillai S; Oresajo C
Cutis; 2010 Sep; 86(3):153-8. PubMed ID: 21049734
[TBL] [Abstract][Full Text] [Related]
18. Single blind, randomized, controlled trial of a lightening product with and without iontophoresis versus tretinoin and vehicle for hyperpigmentation.
Wanner M; Houston N; Javorsky E; Yuan M; Alora-Palli M; Kimball AB
J Drugs Dermatol; 2015 Jan; 14(1):13-8. PubMed ID: 25607903
[TBL] [Abstract][Full Text] [Related]
19. The Safety and Efficacy of Treatment With a 1,927-nm Diode Laser With and Without Topical Hydroquinone for Facial Hyperpigmentation and Melasma in Darker Skin Types.
Vanaman Wilson MJ; Jones IT; Bolton J; Larsen L; Fabi SG
Dermatol Surg; 2018 Oct; 44(10):1304-1310. PubMed ID: 29659405
[TBL] [Abstract][Full Text] [Related]
20. Improved quality of life with effective treatment of facial melasma: the pigment trial.
Balkrishnan R; Kelly AP; McMichael A; Torok H
J Drugs Dermatol; 2004; 3(4):377-81. PubMed ID: 15303781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
